Gilead Sciences Inc. (NASDAQ: GILD), a biopharmaceutical company based in the U.S., has entered into a strategic collaboration with Genesis Therapeutics Inc., an AI-driven drug development firm, to discover and develop innovative small-molecule therapies across a range of therapeutic targets. Under the terms of the agreement, Genesis will receive an upfront cash payment of USD 35 million for the initial three targets, with Gilead holding the option to nominate additional targets for a pre-determined fee per target. Further financial incentives for Genesis include preclinical, development, regulatory, and commercial milestone payments, as well as tiered royalties on any future net sales of the resulting products.
This partnership will leverage Genesis’s proprietary generative AI platform, GEMS (Genesis Exploration of Molecular Space), to generate and optimize molecular candidates for the targets selected by Gilead. GEMS is an advanced platform that integrates proprietary AI techniques, including language models, diffusion models, and physical machine learning simulations, to create and refine molecules tailored for complex therapeutic targets. – Flcube.com
